

**UNITED STATES PATENT AND TRADEMARK OFFICE**

---

**BEFORE THE PATENT TRIAL AND APPEAL BOARD**

---

INTAS PHARMACEUTICALS LTD.,  
Petitioner

v.

ATOSSA THERAPEUTICS, INC.,  
Patent Owner

---

CASE: PGR2023-00043

Patent No. 11,572,334

---

**PATENT OWNER'S MANDATORY NOTICES**

**PURSUANT TO 37 C.F.R. § 42.8**

Pursuant to 37 C.F.R. § 42.8, Patent Owner Atossa Therapeutics, Inc. hereby submits the following mandatory notices in response to the Petition for Post-Grant Review of U.S. Patent No. 11,572,334 (“the ’334 patent”).

**A. Real Party-In-Interest (37 C.F.R. § 42.8(b)(1))**

The patent owner and real party-in-interest is Atossa Therapeutics, Inc.

**B. Related Matters Under 37 C.F.R. § 42.8(b)(2)**

The ’334 patent is not involved in any related litigation matters.

The ’334 patent was filed as U.S. Patent Application No. 17/580,428. The ’334 patent claims the benefits of Provisional Application Nos. 62/693,885, filed Jul. 3, 2018; 62/624,787, filed Jan. 31, 2018; 62/556,884, filed Sept. 11, 2017; and 62/556,799, filed Sept. 11, 2017. The ’334 patent also claims the benefit of PCT/US2018/050272, filed Sept. 10, 2018; and U.S. Patent Application No. 16/641,985, filed Sept. 10, 2018 (now U.S. Patent No. 11,261,151). U.S. Patent Application Nos. 18/090,757 (now U.S. Patent No. 11,680,036) filed Dec. 29, 2022; and 18/128,536, filed Mar. 30, 2023, are continuations of the application leading to the ’334 patent.

**C. Lead and Back-up Counsel Under 37 C.F.R. § 42.8(b)(3)**

<b>Lead Counsel</b>	<b>Back-Up Counsel</b>
Melissa M. Harwood, Ph.D. (Reg. No. 60,229) <a href="mailto:Melissa.Harwood@us.dlapiper.com">Melissa.Harwood@us.dlapiper.com</a>  <u>Postal and Hand-Delivery Address:</u> DLA Piper LLP (US) 701 Fifth Avenue Suite 6900 Seattle, WA 98104-7044 Telephone: (206) 839-4815 Facsimile: (206) 299-4205	Susan M. Krumplitsch ( <i>pro hac vice</i> granted, Paper 9) <a href="mailto:Susan.Krumplitsch@us.dlapiper.com">Susan.Krumplitsch@us.dlapiper.com</a>  <u>Postal and Hand-Delivery Address:</u> DLA Piper LLP (US) 701 Fifth Avenue Suite 6900 Seattle, WA 98104-7044 Telephone: (206) 839-4815 Facsimile: (206) 299-4205

**D. Service Information Under 37 C.F.R. § 42.8(b)(4)**

Service information for lead and back-up counsel is provided in the designation of lead and back-up counsel above. Service of any documents via hand delivery may be made at the postal mailing address of the respective lead and back-up counsel designated above. Patent Owner hereby consents to electronic service by email at [Melissa.Harwood@us.dlapiper.com](mailto:Melissa.Harwood@us.dlapiper.com), [Susan.Krumplitsch@us.dlapiper.com](mailto:Susan.Krumplitsch@us.dlapiper.com), and [SeattlePTABDocket@us.dlapiper.com](mailto:SeattlePTABDocket@us.dlapiper.com).

Patent Owner's Mandatory Notices  
PGR2023-00043  
U.S. Patent No. 11,572,334

Dated: November 8, 2024

Respectfully Submitted,

/Melissa M. Harwood/

Melissa M. Harwood  
Registration Number 60,229  
**DLA Piper LLP (US)**  
701 Fifth Avenue  
Suite 6900  
Seattle, WA 98104-7044  
*Attorney for Patent Owner*

Patent Owner's Mandatory Notices  
PGR2023-00043  
U.S. Patent No. 11,572,334

**CERTIFICATE OF SERVICE**

The undersigned hereby certifies that on this 4th day of November 2024, a true copy of the foregoing instrument was served on Petitioner INTAS PHARMACEUTICALS LTD. by emailing a copy to counsel of record for Petitioner at the email addresses listed below:

Alejandro Menchaca  
[amenchaca@mcandrews-ip.com](mailto:amenchaca@mcandrews-ip.com)

Ben J. Mahon  
[bmahon@mcandrews-ip.com](mailto:bmahon@mcandrews-ip.com)  
[334PGR@mcandrews-ip.com](mailto:334PGR@mcandrews-ip.com)

Dated: November 8, 2024

/Melissa M. Harwood/  
Melissa M. Harwood  
Registration Number 60,229  
[Melissa.Harwood@dlapiper.com](mailto:Melissa.Harwood@dlapiper.com)  
Lead Counsel for Atossa Therapeutics, Inc.